[HT-02-1] Engineering selectivity into therapeutic oligonucleotides through chemical design
Dr. Punit P. Seth heads medicinal chemistry at Ionis Pharmaceuticals. Dr. Seth is co-inventor of Ionis’ Gen 2.5 platform which employs high affinity nucleoside modifications to enhance the affinity, stability and potency of ASOs in the liver and in extra-hepatic tissues. He is also the co-inventor of Ionis’ LICA (ligand conjugated antisense oligonucleotides) platform which enhances ASO potency by targeted delivery to cells and tissues of interest. He has extensive experience with using medicinal chemistry strategies to modulate the activity, pharmacokinetics and toxicological properties of oligonucleotide drugs. Dr. Seth is listed as co-author/co-inventor on over 170 peer-reviewed publications and issued patents and patent applications. He has a Ph.D in organic chemistry from The Ohio State University.
抄録パスワード認証
パスワードは抄録集・参加証に記載してあります。